Compare · ABT vs HYPD
ABT vs HYPD
Side-by-side comparison of Abbott Laboratories (ABT) and Hyperion DeFi Inc. (HYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and HYPD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 4222.4x HYPD ($41.5M).
- Over the past year, ABT is down 18.6% and HYPD is down 78.5% - ABT leads by 59.9 points.
- ABT has been more active in the news (12 items in the past 4 weeks vs 9 for HYPD).
- ABT has more recent analyst coverage (25 ratings vs 2 for HYPD).
- Company
- Abbott Laboratories
- Hyperion DeFi Inc.
- Price
- $100.68+1.91%
- $2.76-1.08%
- Market cap
- $175.37B
- $41.5M
- 1M return
- +11.09%
- -14.15%
- 1Y return
- -18.60%
- -78.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 9
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest HYPD
- Hyperion DeFi Enters Agreement with Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service
- Hyperion DeFi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Walters Happy David was granted 58,917 shares, increasing direct ownership by 53% to 170,847 units (SEC Form 4)
- Director Strahlman Ellen R was granted 58,917 shares, increasing direct ownership by 65% to 150,078 units (SEC Form 4)
- Director Jacobson Rachel was granted 58,917 shares, increasing direct ownership by 105% to 115,218 units (SEC Form 4)
- Director Geltzeiler Michael S was granted 58,917 shares, increasing direct ownership by 67% to 146,932 units (SEC Form 4)
- Hyperion DeFi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.
- Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
- Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets